海洋衍生的作为抗癌候选者,通过通过低氧诱导因素的抑制来破坏低氧信号
Maria Rita Garcia1,2,3, Paula B Andrade1, Florence Lefranc4
1REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.
Marine drugs
|April 26, 2024
概括
海洋天然产品通过抑制缺氧诱导因素 (HIF-1和HIF-2),推动瘤生长和转移,显示出作为抗癌剂的希望. 对这些化合物的进一步研究可能会导致新的癌症疗法.
科学领域:
- 海洋天然产品 海洋天然产品
- 药品化学 药品化学 是一个
- 癌症生物学 癌症生物学
背景情况:
- 瘤缺氧促进癌细胞存活和转移,导致临床结果差.
- 缺氧诱导因子 (HIF-1和HIF-2) 是瘤血管生成和转移的关键调节者,使它们成为有吸引力的治疗点.
- 海洋生物是天然产品的丰富来源,具有潜在的抗癌性质.
研究的目的:
- 批判性地分析来自海洋的HIF-1和HIF-2抑制剂.
- 探索海洋来源的缺氧选择性化合物作为潜在的抗癌剂.
- 确定可以作为开发改进癌症治疗方法的模板的海洋天然产品.
主要方法:
- 针对HIF途径的海洋自然产品的文献综述.
- 分析海洋化合物的抗癌性质和分子机制.
- 对癌症治疗的治疗潜力的评估.
主要成果:
- 海洋天然产品,特别是HIF抑制剂,显示出显著的抗癌潜力.
- 几种海洋化合物对瘤缺氧和相关过程表现出有希望的活性.
- 虽然许多海洋天然产品表现出一般细胞毒性,但很少有针对特定分子标的特征.
结论:
- 海洋天然产品为发现新型HIF抑制剂和缺氧选择性抗癌剂提供了宝贵的资源.
- 对这些化合物的分子机制进行进一步的研究对于药物开发至关重要.
- 来自海洋的化合物可以作为开发下一代癌症化疗药物的结构.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K


